• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

PGxAI Announces Andromeda Precision Prescribing Platform Is Qualified on Mayo Clinic Platform

by Jasmine Pennic 08/24/2026 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
PGxAI Announces Andromeda Precision Prescribing Platform Is Qualified on Mayo Clinic Platform

What You Should Know

  • PGxAI, an AI-native precision medicine company specializing in personalized prescribing and human drug-metabolism intelligence, announced that its Andromeda clinical decision-support platform is now a Qualified Solution on Mayo Clinic Platform.
  • The qualification via Mayo Clinic Platform’s Solutions Studio provides PGxAI with a structured framework for provider-led evaluation, algorithmic validation, clinical workflow integration, and deployment readiness across health systems.
  • Andromeda unifies pharmacogenomics (PGx), multi-omics datasets, phenoconversion-related factors, drug-drug and drug-condition interactions, real-world evidence (RWE), and clinical context into an auditable, clinician-reviewable decision layer embedded directly into electronic health record (EHR) prescribing workflows.
  • The platform addresses trial-and-error medicine by optimizing initial therapy selection, precise metabolic dosing, and adverse drug event (ADE) mitigation across health systems, payers, clinical laboratories, and biopharmaceutical sponsors.
  • PGxAI was co-founded by Dr. Mike Zack, M.D., Ph.D., MPH (a top 1% cited precision medicine scientist) and Allan Gobbs (life sciences entrepreneur with nine exits, including five IPOs).

Multi-Omics Ingestion, Phenoconversion Accounting, and Mayo Clinic Validation

Andromeda translates high-dimensional biological and pharmacological data into in-workflow decision support:

  • Unified Multi-Omics and Phenoconversion Engine: Integrates patient-specific pharmacogenomics, transcriptomic/metabolomic markers, and real-time clinical variables (such as concurrent medications, liver/kidney function, and inflammatory markers) to account dynamically for drug-drug interactions and enzymatic phenoconversion.
  • Clinician-Reviewable Transparency: Employs an explainable AI architecture with auditable data lineage and verifiable medical citations, ensuring the final prescribing authority and clinical judgment remain firmly with the physician.
  • Seamless In-Workflow Prescribing Integration: Designed to embed natively within major EHR prescribing and computerized physician order entry (CPOE) systems, surfacing actionable dosage adjustments and safer alternative molecules before an order is signed.
  • Mayo Clinic Platform Qualification: Evaluated through the Solutions Studio program for clinical relevance, algorithmic efficacy, data security, and operational readiness, opening structured pathways for provider-led pilots across major health systems.
  • Enterprise-Scale Life Sciences Utility: Extends precision pharmacology intelligence to biopharma partners to improve clinical trial cohort stratification, predict therapeutic response rates, and de-risk drug development strategies.

“Our goal is to make the right medication and dose the starting point of treatment, rather than the result of months of trial and error,” said Dr. Mike Zack, M.D., Ph.D., MPH, CEO and Co-Founder of PGxAI. “Andromeda makes personalized prescribing practical in everyday clinical care, with transparent reasoning, verifiable sources and the final decision remaining with the clinician.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |